{"transactions":[{"id":1295363,"issuer":{"id":8251,"kind":"organization","name":"Cadrenal Therapeutics, Inc.","symbol":"CVKD"},"owners":[{"id":83896,"kind":"person","name":"Zelenkofske Steven","position":1,"cik":"0001578333","reported_name":"Zelenkofske Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2025-01-24T18:12:17.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These options vest pro rata on a monthly basis over 12 months commencing on February 1, 2025."}],"balance_after":20000,"derivative":{"exercise_price":19.79,"exercise_date":"2025-02-01","expiration_date":"2035-01-22","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001213900-25-006638","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578333/000121390025006638/ownership.xml","form_type":"4"}},{"id":1674973,"issuer":{"id":8251,"kind":"organization","name":"Cadrenal Therapeutics, Inc.","symbol":"CVKD"},"owners":[{"id":83896,"kind":"person","name":"Zelenkofske Steven","position":1,"cik":"0001578333","reported_name":"Zelenkofske Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2024-01-19T19:41:51.000Z","date":"2024-01-18","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These options vest pro rata on a monthly basis over 12 months commencing on February 1, 2024 and vesting fully on January 18, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vest pro rata on a monthly basis over 12 months commencing on February 1, 2024 and vesting fully on January 18, 2025."}],"balance_after":100000,"derivative":{"exercise_price":0.94,"expiration_date":"2034-01-17","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001213900-24-005004","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578333/000121390024005004/ownership.xml","form_type":"4"}},{"id":3299110,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":83896,"kind":"person","name":"Zelenkofske Steven","position":1,"cik":"0001578333","reported_name":"Zelenkofske Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2020-01-29T16:17:09.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On January 28, 2020, Achillion Pharmaceuticals, Inc. (\"Achillion\") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. (\"Alexion\") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right (\"CVR\") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471."}],"balance_after":0,"derivative":{"exercise_price":2.18,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001562180-20-000679","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218020000679/primarydocument.xml","form_type":"4"}},{"id":3299109,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":83896,"kind":"person","name":"Zelenkofske Steven","position":1,"cik":"0001578333","reported_name":"Zelenkofske Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Medical Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2020-01-29T16:17:09.000Z","date":"2020-01-28","kind":"disposition_to_issuer","acquired":false,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On January 28, 2020, Achillion Pharmaceuticals, Inc. (\"Achillion\") consummated a merger pursuant to the merger agreement among Achillion, Alexion Pharmaceuticals, Inc. (\"Alexion\") and Beagle Merger Sub, Inc. Shareholders received (i) cash consideration of $6.30 per share and (ii) one contingent value right (\"CVR\") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471."}],"balance_after":0,"derivative":{"exercise_price":2.49,"expiration_date":"2028-08-20","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001562180-20-000679","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000156218020000679/primarydocument.xml","form_type":"4"}},{"id":3686965,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":83896,"kind":"person","name":"Zelenkofske Steven","position":1,"cik":"0001578333","reported_name":"Zelenkofske Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to buy)","published_at":"2019-01-25T16:51:16.000Z","date":"2019-01-23","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter."}],"balance_after":200000,"derivative":{"exercise_price":2.18,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001209191-19-005374","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000120919119005374/doc4.xml","form_type":"4"}},{"id":3837426,"issuer":{"id":12234,"kind":"organization","name":"ACHILLION PHARMACEUTICALS INC","symbol":"ACHN"},"owners":[{"id":83896,"kind":"person","name":"Zelenkofske Steven","position":1,"cik":"0001578333","reported_name":"Zelenkofske Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Employee stock option","published_at":"2018-08-21T18:25:09.000Z","date":"2018-08-20","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 25% of the original number of shares on the first anniversary of the grant date and as to an additional 6.25% of the original number of shares at the end of each successive three-month period thereafter."}],"balance_after":500000,"derivative":{"exercise_price":2.49,"expiration_date":"2028-08-20","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001209191-18-047839","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070336/000120919118047839/doc4.xml","form_type":"4"}},{"id":3899541,"issuer":{"id":4162,"kind":"organization","name":"uniQure N.V."},"owners":[{"id":83896,"kind":"person","name":"Zelenkofske Steven","position":1,"cik":"0001578333","reported_name":"Zelenkofske Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2018-06-08T08:58:02.000Z","date":"2018-06-06","kind":"sale","acquired":false,"shares":23929,"price":37.14,"value":888723.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by\nthe vesting of restricted share units."},{"field":"shares","element":"transactionShares","label":"F1","text":"As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by\nthe vesting of restricted share units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. 23,829 of such shares were sold in multiple transactions at prices ranging from $36.70 to $37.69, and 100 of such shares were sold at $37.73. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":159458,"source":{"system":"sec-edgar","filing":"0000904454-18-000405","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578333/000090445418000405/edgar.xml","form_type":"4"}},{"id":4084627,"issuer":{"id":4162,"kind":"organization","name":"uniQure N.V."},"owners":[{"id":83896,"kind":"person","name":"Zelenkofske Steven","position":1,"cik":"0001578333","reported_name":"Zelenkofske Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-01-30T12:02:28.000Z","date":"2018-01-26","kind":"grant","acquired":true,"shares":22364,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Option vests 25% on the first anniversary of the date of grant, and 6.25% quarterly thereafter until fully vested, subject to the Reporting Person's continued relationship with the Issuer through such dates."}],"balance_after":22364,"derivative":{"exercise_price":19.39,"expiration_date":"2028-01-26","underlying":"Ordinary Shares","underlying_shares":22364},"source":{"system":"sec-edgar","filing":"0000904454-18-000082","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1578333/000090445418000082/edgar.xml","form_type":"4"}},{"id":4084626,"issuer":{"id":4162,"kind":"organization","name":"uniQure N.V."},"owners":[{"id":83896,"kind":"person","name":"Zelenkofske Steven","position":1,"cik":"0001578333","reported_name":"Zelenkofske Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2018-01-30T12:02:28.000Z","date":"2018-01-26","kind":"grant","acquired":true,"shares":8387,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share.  The restricted share units vest in equal annual installments of 1/3 each, beginning on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such dates."}],"balance_after":183387,"source":{"system":"sec-edgar","filing":"0000904454-18-000082","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578333/000090445418000082/edgar.xml","form_type":"4"}},{"id":4289490,"issuer":{"id":4162,"kind":"organization","name":"uniQure N.V."},"owners":[{"id":83896,"kind":"person","name":"Zelenkofske Steven","position":1,"cik":"0001578333","reported_name":"Zelenkofske Steven","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Ordinary Shares","published_at":"2017-06-07T16:34:25.000Z","date":"2017-06-05","kind":"grant","acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":175000,"source":{"system":"sec-edgar","filing":"0001209191-17-038308","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578333/000120919117038308/doc4.xml","form_type":"4"}}]}